We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.025 | 25.00% | 0.125 | 0.05 | 0.20 | 0.125 | 0.075 | 0.10 | 17,478,376 | 09:05:49 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.32 | 544.67k |
From Apr 2019 to Apr 2024
TIDMBYOT
RNS Number : 3364O
Byotrol PLC
17 May 2018
17(th) May, 2018
Byotrol plc
("Byotrol" or the "Company")
FURTHER PROGRESS IN THE US
MASS MARKET RETAIL TRIAL WITH TARGET
Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that it has secured its first mass market retail trial in the US, for its 24-hour germ-kill surface sanitizer 'Byotrol24'.
The trial is due to take place over approximately 10-12 weeks at the national retailer Target. We are expecting the trial to start next month in approximately 10% of Target's 1,829 stores, following which Target will decide whether it wishes to roll-out into nationwide distribution.
This progress follows on closely from the Company having completed individual US State product registration earlier this month. Byotrol24 received formal approval from the US Environmental Protection Agency in June 2017.
David Traynor, Chief Executive of Byotrol plc comments:
"This is really good news for Byotrol. Target Corporation is one of the leading general merchandise retailers in the US and is well-known for innovation and design; it is a perfect retail match for our brand and an excellent first step in pursuing our US commercialisation ambitions."
Enquiries:
David Traynor - Chief Executive, Byotrol plc 01925 742 000
David Paton - Investor Relations 07714 190 474
finnCap Ltd
020 7220 0500 (Nominated Adviser & Broker)
Geoff Nash/Kate Bannatyne - Corporate Finance
Richard Chambers - Corporate Broking
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.
Founded in 2005, the Company has developed advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTLLFIRELIRLIT
(END) Dow Jones Newswires
May 17, 2018 02:00 ET (06:00 GMT)
1 Year Byotrol Chart |
1 Month Byotrol Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
